# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Needham analyst Gil Blum reiterates Arcellx (NASDAQ:ACLX) with a Buy and maintains $81 price target.
Arcellx (NASDAQ:ACLX) reported quarterly losses of $(0.14) per share which beat the analyst consensus estimate of $(0.51) by 72...
Needham analyst Gil Blum reiterates Arcellx (NASDAQ:ACLX) with a Buy and maintains $81 price target.
Needham analyst Gil Blum reiterates Arcellx (NASDAQ:ACLX) with a Buy and maintains $81 price target.
Needham analyst Gil Blum maintains Arcellx (NASDAQ:ACLX) with a Buy and raises the price target from $72 to $81.
Stifel analyst Benjamin Burnett reiterates Arcellx (NASDAQ:ACLX) with a Buy and maintains $82 price target.
Morgan Stanley initiates coverage on Arcellx. Uncover the potential of ddBCMA in blood cancer treatment, featuring a differenti...
Morgan Stanley analyst Judah Frommer initiates coverage on Arcellx (NASDAQ:ACLX) with a Overweight rating and announces Pric...